Patterns of Acute Decompensation in Hospitalized Patients with Cirrhosis and Course of Acute-on-chronic Liver Failure
Overview
Authors
Affiliations
Introduction: Recently, based on data from the PREDICT study, the European Foundation for the Study of Chronic Liver Failure (EF-CLIF) consortium proposed pathophysiological/prognostic groups in hospitalized patients with cirrhosis: stable decompensated cirrhosis (SDC), unstable decompensated cirrhosis (UDC), pre-acute-on-chronic liver failure (pre-ACLF), and ACLF. We evaluated the outcomes of these subgroups in a real-life cohort of hospitalized patients with cirrhosis.
Methods: Patients with cirrhosis developing first AD between 09/2010 and 12/2017 at the Vienna General Hospital were evaluated for this retrospective analysis.
Results: Two hundred and ten patients with cirrhosis (aged 57.6 ± 11.8 years) including n = 45 (21.4%) SDC, n = 100 (47.6%) UDC, n = 28 (13.3%) pre-ACLF, and n = 37 (17.6%) with ACLF were considered. The proposed AD subgroups discriminated between patients with favorable (1-year mortality: SDC: 6.7% and UDC: 19.6%) and dismal prognosis (90-day mortality: pre-ACLF: 42.9%). Interestingly, systemic inflammation gradually increased (e.g., C-reactive protein, SDC: 0.9 mg/dl, vs. UDC: 2.0 mg/dl vs. pre-ACLF: 3.2 mg/dl, p < 0.001) while renal function was progressively deteriorating (creatinine levels, SDC: 0.8 mg/dl vs. UDC: 0.9 mg/dl vs. pre-ACLF: 1.2 mg/dl, p < 0.001) across prognostic subgroups in patients with cirrhosis.
Discussion: The recently proposed pathophysiological/prognostic EF-CLIF subgroups are also reproduceable in a real-life cohort of cirrhotic patients. As ACLF is a common and important complication, patients at risk of pre-ACLF at index AD should be evaluated and if disease proceeds, been treated early and aggressively to avoid excessive mortality.
Use of the CytoSorb adsorber in patients with acute-on-chronic liver failure.
Haselwanter P, Scheiner B, Balcar L, Semmler G, Riedl-Wewalka M, Schmid M Sci Rep. 2024; 14(1):11309.
PMID: 38760460 PMC: 11101465. DOI: 10.1038/s41598-024-61658-3.
Acute and non-acute decompensation of liver cirrhosis (47/130).
Schulz M, Angeli P, Trebicka J Liver Int. 2024; 45(3):e15861.
PMID: 38426268 PMC: 11815624. DOI: 10.1111/liv.15861.
Xu M, Chen Y, Artru F United European Gastroenterol J. 2024; 12(2):194-202.
PMID: 38376886 PMC: 10954432. DOI: 10.1002/ueg2.12538.
Kim J, Kim S, Song D, Kim H, Yoon E, Kang S Diagnostics (Basel). 2024; 14(1).
PMID: 38201324 PMC: 10795755. DOI: 10.3390/diagnostics14010014.
Hartl L, Simbrunner B, Jachs M, Wolf P, Bauer D, Scheiner B JHEP Rep. 2023; 6(1):100954.
PMID: 38125301 PMC: 10733101. DOI: 10.1016/j.jhepr.2023.100954.